## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

3235-0287 Estimated average burden 0.5 hours per response

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BAILEY DON M  (Last) (First) (Middle)  1300 NORTH KELLOGG DRIVE, SUITE D					QI QC 3. 0	Issuer Name and Ticker or Trading Symbol     QUESTCOR PHARMACEUTICALS INC [     QCOR ]      Date of Earliest Transaction (Month/Day/Year)     08/14/2014										ıble)		10% Ow Other (s below)	ner	
(Street) ANAHE (City)	ANAHEIM CA 92807  City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)  ative Securities Acquired, Disposed of, or Benefic									Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person  ially Owned					
1. Title of Security (Instr. 3)  2. Transplate (Month/t				saction	1	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Trans Code	3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amount Securities Beneficial Owned For Reported	i lly	Form: Direct I (D) or Indirect I (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									v	Amount	unt (A) or Pi		rice	Transaction(s) (Instr. 3 and 4)				ilisu. 4)		
Common Stock				08/14	08/14/2014				D <sup>(1)</sup>		99,00	0 I		(1)	C	0		I   1	Held by the Bailey 1995 Family Trust	
Common Stock 08/1				4/201	L4			<b>D</b> <sup>(2)</sup>		116,93	37 I		(2)	0			D			
Common Stock 08/14				4/201	4/2014					53,00	0 I		(3)		0		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	ansaci	action (Instr.		Derivative		6. Date Exercisa Expiration Date (Month/Day/Year		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s ully	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Ame or Nun of S			(Instr. 4)	on(s)			
Stock Option (right to buy)	\$5.12	08/14/2014		D	(4)(5)			100,000	(6)		01/18/2020	Common Stock	100	),000	(4)(5)	0		D		
Stock Option (right to buy)	\$14.24	08/14/2014		D	(4)(5)			324,479	(7)		02/15/2021	Common Stock	324	1,479	(4)(5)	0		D		

\$35.78

08/14/2014

Stock

(right to buy

1. Pursuant to Agreement and Plan of Merger, dated April 5, 2014 (the "Merger Agreement"), by and among Mallinckrodt plc ("Mallinckrodt"), Quincy Merger Sub, Inc. and Questcor Pharmaceuticals, Inc. ("Questcor"), Mallinckrodt acquired Questcor in a merger transaction (the "Merger") which closed at 4:30 p.m. EST, on August 14, 2014 (the "Effective Time"). At the Effective Time, each share of Questcor common stock (except for certain shares defined in the Merger Agreement) converted into the right to receive, without interest, (a) \$30.00 in cash and (b) 0.897 of an ordinary share of Mallinckrodt, in exchange for such share of Questcor common stock ("Merger Consideration").

02/14/2022

276,041

D<sup>(4)(5)</sup>

- 2. Pursuant to terms of the Merger, at the Effective Time, each outstanding Questcor restricted share award (other than any such award subject to performance-based vesting conditions) held by Questcor executive officers converted into a number of restricted Mallinckrodt ordinary shares determined by multiplying the applicable number of restricted shares of Questcor common stock by the Equity Award Exchange Ratio.
- 3. Pursuant to terms of the Merger, at the Effective Time, each outstanding Questcor restricted share award held by a Questcor executive that is subject to performance-based vesting conditions was cancelled and converted into the right to receive Merger Consideration in respect of each share of Questcor common stock underlying the Questcor restricted share award.
- 4. Pursuant to terms of the Merger, at the Effective Time, each vested Questcor stock option held by Questcor executive officers converted into the right to receive the Merger Consideration with respect to each share of Company common stock subject to such option immediately prior to the effective time of the Merger, net of the applicable exercise price, while each unvested Questcor stock option held by Questcor executive officers converted into an option to acquire, on the same terms and conditions as were applicable to such option immediately prior to the Effective Time, a number of Mallinckrodt ordinary shares determined by multiplying the number of shares of Questcor common stock subject to such option immediately prior to the effective time of the Merger by the Equity Award Exchange Ratio,
- 5. (Continued from footnote 4) at an exercise price per share of Mallinckrodt ordinary shares (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (x) the exercise price per share of Questcor common stock of such Questcor stock option by (y) the Equity Award Exchange Ratio.
- 7. The stock option is exercisable as it vests 25% of the shares subject to the stock option vest on the first anniversary of the grant date, while the remaining 75% of the shares vest in equal monthly installments over the following 36 months, so that all of the shares become fully vested on the fourth anniversary of the grant date of February 16, 2011.
- 8. The stock option is exercisable as it vests 25% of the shares subject to the stock option vest on the first anniversary of the grant date, while the remaining 75% of the shares vest in equal monthly installments over the following 36 months, so that all of the shares become fully vested on the fourth anniversary of the grant date of February 15, 2012.

#### Remarks:

276,041

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.